Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ModernaTX, Inc.
Data collected from the JMDC Claims database from May 2020 to October 2022.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants registered to receive the mRNA-1273 vaccine in the Pep Up vaccination history Database
Participants who have a history of vaccination with the mRNA-1273 vaccine in the Pep-Up vaccination history Database and the observation start date is at least 6 months prior to vaccination with the mRNA-1273 vaccine and have underlying diseases.
You may not be if
Underlying diseases that were determined undetectable by the pre-screening of JMDC
Participants who did not consent to the questionnaire.
Clareo Health | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
